Yousif Capital Management LLC Sells 3,323 Shares of Danaher Co. (NYSE:DHR)

Yousif Capital Management LLC lowered its holdings in Danaher Co. (NYSE:DHR) by 4.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 73,845 shares of the conglomerate’s stock after selling 3,323 shares during the period. Yousif Capital Management LLC’s holdings in Danaher were worth $16,951,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Sargent Investment Group LLC grew its position in shares of Danaher by 10.5% in the 4th quarter. Sargent Investment Group LLC now owns 13,958 shares of the conglomerate’s stock valued at $3,348,000 after acquiring an additional 1,322 shares during the period. Ninety One UK Ltd grew its position in shares of Danaher by 3.4% in the 4th quarter. Ninety One UK Ltd now owns 134,189 shares of the conglomerate’s stock valued at $30,803,000 after acquiring an additional 4,434 shares during the period. E. Ohman J or Asset Management AB grew its position in shares of Danaher by 8.6% in the 4th quarter. E. Ohman J or Asset Management AB now owns 29,260 shares of the conglomerate’s stock valued at $6,717,000 after acquiring an additional 2,310 shares during the period. Mather Group LLC. grew its position in shares of Danaher by 6.8% in the 4th quarter. Mather Group LLC. now owns 9,540 shares of the conglomerate’s stock valued at $2,190,000 after acquiring an additional 609 shares during the period. Finally, Rockline Wealth Management LLC grew its position in shares of Danaher by 5.6% in the 4th quarter. Rockline Wealth Management LLC now owns 6,713 shares of the conglomerate’s stock valued at $1,541,000 after acquiring an additional 356 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

DHR stock opened at $215.05 on Wednesday. The company has a 50 day simple moving average of $234.93 and a 200 day simple moving average of $252.88. The stock has a market cap of $155.33 billion, a price-to-earnings ratio of 40.73, a P/E/G ratio of 2.80 and a beta of 0.83. Danaher Co. has a 1 year low of $210.04 and a 1 year high of $281.70. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05.

Danaher (NYSE:DHR) last released its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the previous year, the business posted $2.09 earnings per share. Research analysts anticipate that Danaher Co. will post 7.77 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.50%. The ex-dividend date was Friday, December 27th. Danaher’s payout ratio is 20.45%.

Insider Activity

In related news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at $4,534,149.90. The trade was a 21.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 10.90% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on DHR. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Stephens reaffirmed an “overweight” rating and set a $315.00 target price on shares of Danaher in a report on Wednesday, October 23rd. Stifel Nicolaus lifted their target price on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday, October 23rd. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price for the company in a report on Friday, December 13th. Finally, Jefferies Financial Group dropped their price objective on shares of Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a research note on Wednesday, January 29th. Seven investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and an average target price of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.